Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma
null
Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
null
Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug
null
Biomica Opens Second Site to Advance Its Immuno-Oncology Drug Trials at Davidoff Center
#Partners #Expand
Biomica Announces Interim Positive Results from Pre-Clinical Studies in its Irritable Bowel Syndrome (IBS) Program
#Partners #Expand
Biomica Announces Closing of $20 Million Financing Round led by Shanghai Healthcare Capital
#Investment
Biomica Raises $20M to Advance its Pipeline of Microbiome-based Therapeutics
#Investment #Expand
Biomica CEO to Participate in an Industry Panel Discussion at Microbiome Connect USA 2022 Summit - Evogene (NASDAQ:EVGN)
#Investment
Biomica Announces Successful Enrollment of First Patient in its Phase I Study of Microbiome-Based Immuno-Oncology Drug
#Customers
Biomica to Present at the 7th Microbiome Movement Drug Development Summit
#Partners
Biomica Announces Agreement with Sheba Medical Center for Joint Microbiome Clinical Research | BioSpace
#Partners
Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination with Bristol Myers Squibb's Anti-PD-1 Opdivo®
#Partners #Investment
Biomica &Rambam Health Care Campus Sign Agreement for Clinical Trial of Biomica's Microbiome-Based Immuno-Oncology Drug
#Partners
Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127 for its Immuno-Oncology Program
#Partners #Expand
Biomica Reports Positive Preliminary Results in Animal Studies in Its Immuno-oncology Program
#Investment
Evogene teams with Weizmann Nobel laureate on microbiomes
#Partners
Biomica To Collaborate with Weizmann Institute of Science to Develop A Selective Treatment Against Antibiotic Resistant Bacteria - Evogene
#Partners
Biomica Announces Advancement to Pre-Clinical Studies in its Inflammatory Bowel Disease Program - Evogene
#Management Changes, Expand
Biomica Announces the Addition of Internationally Renowned Experts in the Fields of Gastroenterology and the Human Microbiome to its Scientific Advisory Board
#Management Changes #Expand
Biomica, Evogene's Newly Established Subsidiary, Announces Therapeutic Areas of Focus
#Investment, Expand
Evogene unit Biomica designs molecules to analyze bacteria
#Investment, Partners